Canada: Tribunal dismisses Eli Lilly’s NAFTA challenge

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Canada: Tribunal dismisses Eli Lilly’s NAFTA challenge

Following the invalidation of its patents for Strattera (atomoxetine) and Zyprexa (olanzapine), Eli Lilly and Company submitted claims to international arbitration under the North American Free Trade Agreement (NAFTA). On March 1, 2017, the Tribunal issued its final award dismissing Eli Lilly's claims.

Eli Lilly's patents were invalidated on the basis of the so-called "promise of the patent" doctrine; namely, that the claims of the patent failed to deliver utility promised by statements in the specification. Eli Lilly argued that Canadian courts had dramatically changed the application of the utility requirement through a series of cases that adopted the promise doctrine and that the retroactive application of this doctrine to Eli Lilly's patents resulted in a breach of Canada's obligations under NAFTA.

The Tribunal, however, found that Canada's utility requirement underwent incremental and evolutionary changes between the grant of the patents and their subsequent invalidation. Moreover, it found that the promise standard has a "strong foundation" in earlier jurisprudence of the Supreme Court of Canada. Further, the Tribunal found that the doctrine was neither arbitrary nor discriminatory. In summary, the government of Canada was not found to have violated its obligations under NAFTA.

The NAFTA decision further supports the application of the heightened utility requirement that may arise under Canadian law through application of the promise doctrine. Those interested in the issue, however, eagerly await a decision from the Supreme Court of Canada in the case of AstraZeneca Canada Inc v Apotex Inc. In that case, which was heard in November 2016, the promise doctrine was directly before the Supreme Court. A decision, which may bring some clarity on the issue, is expected soon.

Neil Padgett

Smart & Biggar/ Fetherstonhaugh

55 Metcalfe Street Suite 900

PO Box 2999 Station D

Ottawa ON  K1P 5Y6

Tel: 613 232 2486

Fax: 613 232 8440 

ottawa@smart-biggar.ca

www.smart-biggar.ca

more from across site and SHARED ros bottom lb

More from across our site

Alston & Bird acted for InterDigital, while Samsung was represented by Fish & Richardson, during the arbitration process
Powell Gilbert lawyers reveal how they navigated parallel EPO proceedings and collaborated with European peers to come out on top in the Nordic-Baltic Division’s first judgment
The firms posted increases in revenue and profit per equity partner, with both giving a nod to their IP expertise
EasyGroup, the owner of the easyJet airline, said in a press release that UK-based first-instance judges are “less experienced”, bringing a long-running debate back to the fore
A cross-practice team from Mayer Brown, which included members of the firm’s IP practice, advised on the deal
María Cecilia Romoleroux discusses the challenges she has faced in her career in IP and how she hopes to improve things for the next generation of women
Value-added services give in-house counsel the satisfaction that they are getting more value for money, while law firms get the opportunity to win more work
A team at Boies Schiller Flexner is advising shoe company Kizik and parent company HandsFree Labs in the dispute
Nokia’s latest enforcement actions against Geely and Transsion joining Via LA’s AAC pool were also among the top talking points
Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Gift this article